Ethan M. Balk, MD, MPH; Joseph Lau, MD; Leonidas C. Goudas, MD, PhD; Harmon S. Jordan, ScD; Bruce Kupelnick, BA; Linda U. Kim, BA; Richard H. Karas, MD, PhD
Grant Support: By RxIntelligence (www.rxintelligence.com), a nonprofit organization dedicated to providing independent, objective information comparing the costs and effectiveness of pharmaceuticals.
Potential Financial Conflicts of Interest:Consultancies: R.H. Karas (Merck & Co., Pfizer); Honoraria: R.H. Karas (Merck & Co., Pfizer); Stock ownership or options (other than mutual funds): J. Lau (Merck & Co., Pfizer); Grants received: R.H. Karas (Merck & Co.).
Corresponding Author: Joseph Lau, MD, Tufts-New England Medical Center, Box 63, 750 Washington Street, Boston, MA 02111.
Current Author Addresses: Drs. Lau and Balk, Mr. Jordan, and Mr. Kupelnick: Tufts-New England Medical Center, Box 63, 750 Washington Street, Boston, MA 02111.
Dr. Karas: Tufts-New England Medical Center, Box 80, 750 Washington Street, Boston, MA 02111.
Dr. Goudas: Tufts-New England Medical Center, Box 298, 750 Washington Street, Boston, MA 02111.
Ms. Kim: Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111.
Statins reduce cardiovascular events to a greater extent than can be explained by their effect on lipids. Several studies have attempted to elucidate mechanisms by which statins reduce cardiovascular risk.
To summarize the effects of statins on nonlipid serum markers and to correlate statins' effect on serum markers with lipid levels and cardiovascular outcomes.
MEDLINE (1980 to 2003) search limited to English-language articles.
Studies reporting original data in at least 10 participants on the effect of statins on outcomes of interest, excluding studies of cerivastatin, drug combinations, and patients with organ transplants.
Study design, sample size, treatment, and outcome data extracted on the basis of preestablished criteria. When appropriate, meta-analysis was performed by using a random-effects model.
All statins are effective at lowering C-reactive protein levels, and the effect is not dose-dependent. Studies do not demonstrate a correlation between statins' effects on C-reactive protein levels and on lipids or cardiovascular outcomes. Statins do not affect fibrinogen levels, and limited data suggest little effect on lipid oxidation, tissue plasminogen activator, or plasminogen activator inhibitor. Platelet aggregation data are inconclusive.
Among nonlipid serum markers examined, only C-reactive protein levels are statistically significantly affected by statins. These findings suggest that statin-mediated anti-inflammatory effects may contribute to the ability of statins to reduce risk for cardiovascular disease. Overall, however, available data are insufficient to support recommendations for using nonlipid serum markers in decisions regarding statin therapy for individual patients.
Balk EM, Lau J, Goudas LC, Jordan HS, Kupelnick B, Kim LU, et al. Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease: A Systematic Review. Ann Intern Med. 2003;139:670–682. doi: 10.7326/0003-4819-139-8-200310210-00011
Download citation file:
Published: Ann Intern Med. 2003;139(8):670-682.
Cardiology, Coronary Risk Factors, Dyslipidemia.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use